FDA Approves Xocova for COVID-19 Postexposure Prophylaxis

MONDAY, June 8, 2026-- The U.S. Food and Drug Administration has approved Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and adolescents aged 12 years and older.Xocova is approved as a five-day...